#3 - Bristol-Myers Squibb (NYSE:BMY)
Next up on this list of attractive stocks to buy at their 52-week low is Bristol-Myers Squibb (NYSE: BMY). The stock is down approximately 21% in 2024, with most of the losses occurring since the company's April 2024 earnings report. The topline number was fine, showing slight YOY growth.
Earnings, however, were a different story. The company posted a loss of $4.40 per share due to the company's acquisition spree that closed in the quarter. Plus, while Bristol-Myers Squibb has one of the industry's largest and deepest pipelines, it faces some expiring patents.
Putting that issue aside, there are still reasons to consider BMY stock. One is the company's pipeline, which is heavy on oncology drugs and which the company's recent acquisitions will only help expand. Second, the company is working to make drugs more accessible in low—and middle-income countries.
However, its simple value is even more important when considered in a significant area. From a technical standpoint, BMY is trading at a five-year low, which analysts clearly believe is a buying opportunity. Plus, investors get a dividend with a 5.93% yield.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More - Current Price
- $58.23
- Consensus Rating
- Hold
- Ratings Breakdown
- 4 Buy Ratings, 14 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $54.07 (7.1% Downside)
